Tse Victor, Sillanpaa Jussi, Minn Ann Y, Teng Ming, Xiaoyang Fu, Gillis Amy, Millender Laura, Sheridan William, Wara William
Department of Radiation Oncology, Kaiser Permanente Comprehensive Cancer Treatment Center, 220 Oyster Point Blvd., South San Francisco, CA 94080, USA.
Department of Neurosurgery, Kaiser Permanente Northern California Neuroscience Center, Tower Building 3rd Floor, 1150 Veterans Blvd., Redwood City, CA 94063, USA.
J Radiosurg SBRT. 2017;5(1):73-81.
Glomus tumors are difficult to manage surgically because they are vascular tumors that are topographically associated with important vascular and neuronal structures. Hence, there is a strong risk of incomplete resection and a high morbidity rate. In addition, they grow slowly. Recent treatments have increasingly involved a combination of surgical resection and radiosurgery. We present our experience in treating glomus tumors of the skull base with stereotactic radiosurgery as an upfront therapy.
We analyzed data from 13 consecutive patients with glomus tumors that were initially treated with stereotactic radiosurgery in our institute from February 2010 to April 2012. The tumor control rate, resolution of symptoms, and the complication rate were tabulated.
All patients were female with a median age of 63 (mean 62.7+/-14.6 years). The median treatment dose was 25.8 Gy (27.6 Gy +/- 9.5 Gy) and the median tumor volume 10.4 mL (9.2 +/- 6.5). The median follow-up was 47.4 months (51.8+/-11.2 months, range 31-74). The tumor control rate was 92.3%; 46.7% of the patients had noticeable tumor shrinkage. This happened at a median interval of 17 months (18.7+/-6.8) after treatment. Most patients with tinnitus had resolution of their symptoms (87.5%). Four patients presented with new symptoms and four patients with worsening of pre-existing symptoms. The time course of symptomatic improvement followed that of tumor size reduction. However, there was no statistical correlation between the amount of tumor reduction and symptomatic relief.
Stereotactic radiosurgery (SRS) is an effective upfront treatment option in the management of glomus tumors.
球瘤手术治疗困难,因为它们是血管性肿瘤,在局部解剖位置上与重要的血管和神经结构相关。因此,存在切除不完全的高风险和高发病率。此外,它们生长缓慢。最近的治疗越来越多地采用手术切除和放射外科相结合的方法。我们介绍我们使用立体定向放射外科作为初始治疗方法治疗颅底球瘤的经验。
我们分析了2010年2月至2012年4月在我院最初接受立体定向放射外科治疗的13例连续性球瘤患者的数据。将肿瘤控制率、症状缓解情况和并发症发生率制成表格。
所有患者均为女性,中位年龄63岁(平均62.7±14.6岁)。中位治疗剂量为25.8 Gy(27.6 Gy±9.5 Gy),中位肿瘤体积为10.4 mL(9.2±6.5)。中位随访时间为47.4个月(51.8±11.2个月,范围31 - 74个月)。肿瘤控制率为92.3%;46.7%的患者肿瘤有明显缩小。这发生在治疗后中位间隔时间17个月(18.7±6.8个月)。大多数耳鸣患者症状得到缓解(87.5%)。4例患者出现新症状,4例患者原有症状加重。症状改善的时间进程与肿瘤大小缩小的时间进程一致。然而,肿瘤缩小量与症状缓解之间无统计学相关性。
立体定向放射外科(SRS)是治疗球瘤的一种有效的初始治疗选择。